We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+1.74%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$7.1B
AUM Growth
+$59.7M
Cap. Flow
-$1.53B
Cap. Flow %
-21.52%
Top 10 Hldgs %
75.68%
Holding
101
New
15
Increased
16
Reduced
17
Closed
6

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$78.6M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$57.7M
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$22.5M
4
DYAX
DYAX CORPORATION
DYAX
+$15.4M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$13.6M

Top Sells

Rank Stock Value
1
VPHM
VIROPHARMA INC
VPHM
+$220M
2
GILD icon
Gilead Sciences
GILD
+$48M
3
PCYC
PHARMACYCLICS INC
PCYC
+$35.3M
4
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$24.5M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$24.5M

Sector Composition

Rank Sector Weight
1 Healthcare 50.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDSI
51
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$4.98M 0.07%
846,005
– –
AGIO icon
52
Agios Pharmaceuticals
AGIO
$1.98B
$4.93M 0.07%
205,750
+5,750
+3% +$131K
VXRT
53
DELISTED
Vaxart
VXRT
$4.74M 0.07%
+102,738
New +$4.52M
ASMB icon
54
Assembly Biosciences
ASMB
$700M
$4.64M 0.07%
20,264
– –
EPZM
55
DELISTED
Epizyme, Inc
EPZM
$4.58M 0.06%
220,000
+200,000
+1,000% +$5.8M
ABUS icon
56
Arbutus Biopharma
ABUS
$1.03B
$3.98M 0.06%
+500,000
New +$4.16M
GWPH
57
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$3.91M 0.06%
+94,172
New +$2.98M
LGND icon
58
Ligand Pharmaceuticals
LGND
$5.71B
$3.86M 0.05%
117,660
– –
ISEE
59
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$3.33M 0.05%
+103,040
New +$3.06M
ENTA icon
60
Enanta Pharmaceuticals
ENTA
$392M
$2.98M 0.04%
109,097
-15,903
-13% -$385K
RCPT
61
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$2.9M 0.04%
100,000
– –
MGNX icon
62
MacroGenics
MGNX
$261M
$2.74M 0.04%
+100,000
New +$2.62M
MDGL icon
63
Madrigal Pharmaceuticals
MDGL
$11.9B
$2.62M 0.04%
14,286
– –
PBYI icon
64
Puma Biotechnology
PBYI
$477M
$2.59M 0.04%
25,000
-75,000
-75% -$4.4M
BLUE
65
DELISTED
bluebird bio
BLUE
$2.4M 0.03%
8,836
+227
+3% +$63.4K
UTHR icon
66
United Therapeutics
UTHR
$22B
$2.26M 0.03%
20,000
-35,984
-64% -$3.24M
ITMN
67
DELISTED
INTERMUNE INC
ITMN
$2.21M 0.03%
+150,000
New +$2.07M
GERN icon
68
Geron
GERN
$977M
$1.91M 0.03%
425,981
-632,019
-60% -$2.71M
OSUR icon
69
OraSure Technologies
OSUR
$268M
$1.53M 0.02%
243,467
– –
ACHN
70
DELISTED
Achillion Pharmaceuticals
ACHN
$1.51M 0.02%
455,000
– –
RIGL icon
71
Rigel Pharmaceuticals
RIGL
$857M
$1.43M 0.02%
50,000
– –
KPTI icon
72
Karyopharm Therapeutics
KPTI
$44.5M
$1.41M 0.02%
+4,089
New +$1.13M
FOLD
73
DELISTED
Amicus Therapeutics
FOLD
$1.21M 0.02%
515,072
– –
XLRN
74
DELISTED
Acceleron Pharma
XLRN
$1.19M 0.02%
+30,000
New +$724K
TCRT icon
75
Alaunos Therapeutics
TCRT
$4.47M
$1.1M 0.02%
1,695
– –
1 2
3
4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2013 Portfolio in Review

As of Q4 2013, Julian Baker held 101 positions worth $7.1B, up 0.85% from $7.04B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Julian Baker withdrew a net $1.53B in Q4 2013, closing 6 positions and reducing 17 holdings. Its most notable exit was VIROPHARMA INC, an estimated $220M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, up from 48% a quarter earlier.

Against the trend, Julian Baker opened a new position in DYAX CORPORATION worth $15.3M.

  • Julian Baker's largest Q4 2013 buy was DYAX CORPORATION: 2,026,537 shares worth $15.3M.
  • Julian Baker added most to BioMarin Pharmaceuticals in Q4 2013, an estimated $78.6M increase.
  • Julian Baker's biggest Q4 2013 reduction was Gilead Sciences, cutting an estimated $48M.
  • Julian Baker fully exited VIROPHARMA INC in Q4 2013, selling an estimated $220M.
  • Julian Baker's ten largest holdings make up 76% of its $7.1B portfolio in Q4 2013.
  • Julian Baker opened 15 new positions and closed 6 in Q4 2013.
  • Julian Baker's portfolio value rose 0.85% quarter-over-quarter to $7.1B.

Based on Baker Bros. Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.